T-cell Inhibition by Mycophenolate Mofetil Treatment in Patients Undergoing Carotid Endarterectomy
Completed
- Conditions
- Vascular diseaseCirculatory System
- Registration Number
- ISRCTN84092396
- Lead Sponsor
- Academic Medical Center (AMC) (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Consecutive patients with carotid artery stenosis (more than 70% diameter stenosis on angiography or ultrasonography) with ipsilateral Transient Ischaemic Attack (TIA) who are planned to undergo Carotid EndArterectomy (CEA) will be included and treated for a minimum of three weeks prior to surgery. These patients will be recruited at the outpatient department of Vascular Surgery.
Exclusion Criteria
Patients who are unable to tolerate MMF treatment, who withdraw their consent or those with any other medical condition or laboratory abnormality which in the opinion of the principal investigator could affect subject safety, preclude evaluation of response, or render unlikely that the patient would complete the study, are excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method After three weeks of treatment: immunostaining for: CD3, CD4, CD8, CD40L, CD69, CD86.
- Secondary Outcome Measures
Name Time Method After three weeks of treatment: immunostaining for endothelial, plaque composition and stability markers.